Loading...
OTCM
NONOF
Market cap310bUSD
Mar 31, Last price  
68.96USD
1D
-0.49%
1Q
-19.72%
Jan 2017
93.16%
Name

Novo Nordisk A/S

Chart & Performance

D1W1MN
P/E
21.23
P/S
7.38
EPS
22.40
Div Yield, %
—
Shrs. gr., 5y
-1.27%
Rev. gr., 5y
18.94%
Revenues
290.40b
+25.03%
33,713,685,04038,751,814,80041,888,774,00045,666,120,40051,078,000,00060,776,000,00066,346,000,00078,026,000,00083,572,000,00088,806,000,000107,927,000,000111,780,000,000111,696,000,000111,831,000,000122,021,000,000126,946,000,000140,800,000,000176,954,000,000232,261,000,000290,403,000,000
Net income
100.99b
+20.68%
5,856,397,4206,452,985,2008,535,266,0009,666,004,40010,768,000,00014,403,000,00017,097,000,00021,432,000,00025,184,000,00026,481,000,00034,860,000,00037,925,000,00038,130,000,00038,628,000,00038,951,000,00042,138,000,00047,757,000,00055,525,000,00083,683,000,000100,988,000,000
CFO
120.97b
+11.07%
8,699,492,4007,741,322,0009,997,870,00012,896,921,20015,378,000,00019,679,000,00021,374,000,00022,214,000,00025,942,000,00031,692,000,00038,287,000,00048,314,000,00041,168,000,00044,616,000,00046,782,000,00051,951,000,00055,000,000,00078,887,000,000108,908,000,000120,968,000,000
Earnings
Apr 30, 2025

Profile

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
URL
https://www.novonordisk.com/
IPO date
May 17, 1974
Employees
59,337
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
290,403,000
25.03%
232,261,000
31.26%
176,954,000
25.68%
Cost of revenue
159,961,000
129,806,000
103,179,000
Unusual Expense (Income)
NOPBT
130,442,000
102,455,000
73,775,000
NOPBT Margin
44.92%
44.11%
41.69%
Operating Taxes
26,203,000
20,991,000
13,537,000
Tax Rate
20.09%
20.49%
18.35%
NOPAT
104,239,000
81,464,000
60,238,000
Net income
100,988,000
20.68%
83,683,000
50.71%
55,525,000
16.27%
Dividends
(44,140,000)
(31,767,000)
(25,303,000)
Dividend yield
Proceeds from repurchase of equity
(20,181,000)
(29,924,000)
(24,086,000)
BB yield
Debt
Debt current
13,113,000
6,478,000
1,466,000
Long-term debt
96,440,000
26,254,000
28,847,000
Deferred revenue
Other long-term liabilities
9,681,000
17,742,000
5,452,000
Net debt
80,568,000
839,000
5,396,000
Cash flow
Cash from operating activities
120,968,000
108,908,000
78,887,000
CAPEX
(47,164,000)
(25,806,000)
(14,753,000)
Cash from investing activities
(128,895,000)
(43,892,000)
(24,918,000)
Cash from financing activities
8,735,000
(63,158,000)
(51,797,000)
FCF
50,099,000
62,309,000
59,972,000
Balance
Cash
26,308,000
30,230,000
23,574,000
Long term investments
2,677,000
1,663,000
1,343,000
Excess cash
14,464,850
20,279,950
16,069,300
Stockholders' equity
143,488,000
106,566,000
83,492,000
Invested Capital
241,489,150
131,029,050
91,561,700
ROIC
55.96%
73.20%
67.15%
ROCE
49.91%
67.71%
64.32%
EV
Common stock shares outstanding
4,463,000
4,494,800
4,544,600
Price
Market cap
EV
EBITDA
138,987,000
111,868,000
81,137,000
EV/EBITDA
Interest
1,640,000
542,000
378,000
Interest/NOPBT
1.26%
0.53%
0.51%